LRMR Stock Forecast & Price Target

Larimar Therapeutics is positioned favorably because nomlabofusp targets the root cause of Friedreich’s ataxia by delivering frataxin, with open-label data showing sustained biomarker restoration and clinical improvement, including 82% of participants reaching carrier-like skin frataxin levels at six months and 100% by one year and 18 months. The regulatory path also looks constructive, as the company has already secured Rare Pediatric Disease, Fast Track, Orphan Drug, and PRIME designations, while management says the pre-BLA feedback supported filing and may allow frataxin as a novel surrogate endpoint. Financially, Larimar ended 1Q26 with $200.4M in cash, cash equivalents, and marketable securities, and the expected 2027 launch could scale toward more than $1.1B in peak annual sales by 2040E.

Larimar Therapeutics is heavily exposed to regulatory and clinical risk because accelerated approval could still require additional or longer studies, and any label that lacks key features may limit commercial traction. The investment case is also constrained by a single-asset profile, with most development centered on nomlabofusp, so safety setbacks or termination of that program would materially damage the company. Competitive pressure from Biogen’s marketed Skyclarys and other gene therapies, plus the need for additional external funding to keep advancing the platform, raises the risk of delays, dilution, or outright development interruption.